Non-Hodgkin Lymphoma | Specialty

The non-hodgkin lymphoma condition center is a comprehensive resource for clinical news and expert insights on non-hodgkin lymphoma. Read more at OncLive.

Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL

December 23rd 2024

Meta: Lori A Leslie, MD, discusses 5-year follow-up data from the ZUMA-5 trial evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL

December 20th 2024

Andrew Ip, MD, discusses comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma.

DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma

December 20th 2024

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL

December 10th 2024

Axi-cel sustained long-term efficacy in relapsed/refractory follicular lymphoma and marginal zone lymphoma.

Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL

December 10th 2024

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL

December 10th 2024

Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.

Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL

December 10th 2024

Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

December 10th 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma

December 9th 2024

Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

December 8th 2024

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL

December 5th 2024

A sBLA has been accepted for review seeking the approval of glofitamab plus gemcitabine and oxaliplatin for pretreated, transplant-ineligible patients with relapsed/refractory DLBCL.

Research Provides Insights Into Real-World CAR T-Cell Therapy and Bispecific Antibody Use in DLBCL

December 3rd 2024

Jennifer Amengual, MD, discusses real-world outcomes with CAR T-cell therapy and bispecific antibodies in patients with DLBCL.

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

November 14th 2024

Transposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

BGB-16673 Shows Early Activity, Tolerability in Heavily Pretreated Waldenström Macroglobulinemia

October 29th 2024

BGB-16673 had acceptable tolerability and showcased early antitumor activity in patients with relapsed/refractory Waldenström macroglobulinemia.

Dr Herrera on Nivolumab vs Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

October 28th 2024

Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma

October 26th 2024

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.